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Objective. To evaluate the gut mucosa and blood-brain barrier (BBB) pharmacokinetic permeability properties of the plant N-
alkylamide pellitorine. Methods. Pure pellitorine and an Anacyclus pyrethrum extract were used to investigate the permeation of
pellitorine through (1) a Caco-2 cell monolayer, (2) the rat gut after oral administration, and (3) the BBB in mice after intravenous
and intracerebroventricular administration. A validated bioanalytical UPLC-MS2 method was used to quantify pellitorine. Results.
Pellitorine was able to cross the Caco-2 cell monolayer from the apical-to-basolateral and from the basolateral-to-apical side with
apparent permeability coefficients between 0.6 ⋅ 10−5 and 4.8 ⋅ 10−5 cm/h and between 0.3 ⋅ 10−5 and 5.8 ⋅ 10−5 cm/h, respectively.
In rats, a serum elimination rate constant of 0.3 h−1 was obtained. Intravenous injection of pellitorine in mice resulted in a rapid
and high permeation of pellitorine through the BBB with a unidirectional influx rate constant of 153 𝜇L/(g⋅min). In particular, 97%
of pellitorine reached the brain tissue, while only 3% remained in the brain capillaries. An efflux transfer constant of 0.05min−1
was obtained. Conclusion. Pellitorine shows a good gut permeation and rapidly permeates the BBB once in the blood, indicating a
possible role in the treatment of central nervous system diseases.
1. Introduction
Pellitorine (deca-2E,4E-dienoic acid isobutylamide, F3M1
according to the FxMy classification of N-alkylamides
(NAAs)) is a highly abundant and biologically potent diene
NAA found inAsteraceae plants such asAnacyclus pyrethrum
(AP) [1]. Various pharmacological activities of pellitorine
have already been reported, namely, antiprotozoal, larvi-
cide, antiseptic, antithrombotic, antituberculosis, antibac-
terial, anticancer, and antiplatelet aggregation properties
and vascular barrier protective effects [2–10]. It was also
demonstrated that pellitorine reduces fatty acid uptake in
vitro [11]. Central nervous system (CNS) activities of purified
pellitorine are not yet described, while a limited number
of CNS activities of Anacyclus pyrethrum extracts have
been reported. Antiseizure activity was demonstrated after
intraperitoneally administration of 100–800mg/kg of the
chloroform fraction of Anacyclus pyrethrum roots to mice.
Other studies with the Anacyclus pyrethrum extract in mice
showed anticonvulsant and myorelaxation activities [12].
Another study with an ethanolic AP root extract showed
anticonvulsant effect against maximal electro shock (MES)
induced convulsions in mice [13]. Sujith et al. [14] found that
the AP root extract possesses antidepressant activity in albino
Wister rats and improves the learning acquisition of rats.
CNS effects of compounds require them to penetrate
the blood-brain barrier in order to reach their brain target.
Compounds can enter the systemic circulation after topical
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and oral administration, by crossing several physiological
barriers (i.e., stratum corneum, intestinal barrier), and fur-
ther reach the brain. A previous study of our research group
demonstrated that pellitorine permeates human skin using an
in vitro Franz diffusion cell (FDC) experiment. The aqueous
permeability coefficient𝐾
𝑝,𝑎𝑞
of pellitorinewas 2.3⋅10−4 cm/h
for the crude plant extract and 1.1 ⋅ 10−4 cm/h for purified
pellitorine [15]. Moreover, the BBB transport kinetics of
spilanthol were studied as well [16].
Up till now, to our best knowledge, no information is
available about the intestinal barrier and blood-brain barrier
transport kinetics of the 2,4-diene N-alkylamide pellitorine.
Hence, the aim of this study was to quantitatively investigate
this in vitro using a Caco-2 cell monolayer as well as in vivo
with an oral gavage rat model and a BBB mice model.
2. Materials and Methods
2.1. Chemicals and Reagents. Dextran was bought from
AppliChem GmbH (Darmstadt, Germany), while trypsin-
EDTA came from Invitrogen (Ghent, Belgium). UPLC-
MS grade acetonitrile (ACN), methanol (MeOH), and
trifluoroacetic acid (TFA) were purchased from Biosolve
(Valkenswaard, Netherlands). Dimethylacetamide and phos-
phoric acid (85%) (H
3
PO
4
) were obtained from Jansen
Chimica (Geel, Belgium), while propylene glycol (PG) was
bought from Riedel-de Hae¨n (Seelze-Hannover, Germany).
Disodium hydrogen phosphate dihydrate (Na
2
HPO
4
⋅2H
2
O),
sodium hydrogen carbonate (NaHCO
3
), sodium dihydrogen
phosphate monohydrate (NaH
2
PO
4
⋅H
2
O), acetic acid, and
absolute ethanol (EtOH, ≥99.9% V/V) were purchased from
Merck KGaA (Darmstadt, Germany), while polyethylene
glycol 400 (PEG 400), calcium dichloride (CaCl
2
), LC-
MS grade formic acid (FA), tween 80, sodium hydroxide
(NaOH), D-glucose, HEPES, Hanks’ Balanced Salt Solution
(HBSS), vitamin E-TPGS, trypan blue, dimethylsulfoxide
(DMSO), sodium chloride (NaCl), potassium chloride (KCl),
phosphate buffered saline (PBS), sodium hydrogen carbon-
ate (NaHCO
3
), calcium chloride dehydrate (CaCl
2
⋅2H
2
O),
sodium lactate, sodium dihydrogen phosphate (NaH
2
PO
4
),
sodium sulphate (Na
2
SO
4
), urethane, Krebs-Henseleit buffer,
and hydrochloric acid (HCl) were bought from Sigma-
Aldrich (Diegem, Belgium). HPLC gradient grade ACN,
MeOH, and absolute ethanol (99.8% V/V) were obtained
from Fisher Scientific (Erembodegem, Belgium). Ultrapure
water (H
2
O) of 18.2 MΩ⋅cm quality was produced by an
Arium 611 purification system (Sartorius, Go¨ttingen, Ger-
many).
2.2. Products Examined. The ethanolic Anacyclus pyrethrum
root extract was prepared and characterised as previously
described [17].The Anacyclus pyrethrum root extract (extract
contains 4.87% w/w NAAs of which pellitorine was the main
NAA (1.55% w/w pellitorine)) was used for the oral gavage
experiment and theCaco-2 cell permeability assay. Pellitorine
was bought fromAdipogen Life Sciences (99.8% purity deter-
mined by HPLC) and was used for the BBB transport assay.
As analytical internal standard (IS), isobutyldecanamide was
used, obtained from the Laboratory of Medicinal Chemistry
(Ghent University). Dermorphin (>95% purity determined
by HPLC) was obtained from Bachem (Bubendorf, Switzer-
land) and bovine serum albumin (BSA) from Merck KGaA
(Darmstadt, Germany); these compounds were used as posi-
tive and negative controls during BBB studies, respectively.
2.3. In Vitro Permeation Study in Caco-2 Cell Monolayers
2.3.1. Cell Culture. The Caco-2 cell line originated from a
human colorectal carcinoma and was maintained in Dul-
becco’s modified Eagle’s medium (DMEM) (95% humidity,
37∘C, 5% CO
2
), supplemented with 10% (V/V) fetal bovine
serum, 100U/mL penicillin and 100 𝜇g/mL streptomycin,
2mM L-glutamine, and 1% nonessential amino acids (all
from Invitrogen/GIBCO, Ghent, Belgium).
2.3.2. Caco-2 Cell Permeability Assay. TheCaco-2 cell intesti-
nal model was used to investigate the gut mucosa permeation
of pellitorine. On each Transwell (Corning Costar, New York,
USA) membrane insert filter (0.4 𝜇m pore size, 12mm filter
diameter), the cells were seeded at a density of 2.6 ⋅ 105
cells/cm2 cells and cultivated in the described supplemented
DMEM. Every second day, the mediumwas changed. During
a period of 21–29 days, the cells were grown and differen-
tiated until monolayers were formed. The integrity of the
monolayers was checked via the measurement of transep-
ithelial electrical resistance (TEER) of the monolayers with
a Millicell-ERS system (Millipore Corp., Bedford, MA, USA)
before and after the transport experiments. The experiments
were performed in duplicate for each dose solution. Transport
experiments were carried out according to Hubatsch et al.
[18] in two directions: from the apical-to-basolateral (ab)
direction and from the basolateral-to-apical (ba) direction
in Hanks’ Balanced Salt solution. Two dose solutions of
pellitorine (in Anacyclus pyrethrum extract) of 1 𝜇g/mL in
0.5% EtOH (further indicated as DS1) and of 56𝜇g/mL in
0.5% of a mixture of vitamin E-TPGS (33.3%), EtOH (11.1%),
PEG 400 (33.3%), and PG (22.2%) (further indicated as DS2)
dissolved in HBSS were tested.
Final apical volumes of 0.4mL and basolateral volumes
of 1.2mL were used for 12 mm filter supports during the
transport experiment. After 15, 30, 60, 90, and 120min, sam-
ples were taken from the receiver compartment (basolateral
to apical transport: 100 𝜇L, apical-to-basolateral transport:
300 𝜇L) and immediately replaced by fresh HBSS. After
120min, a sample from the donor compartment was taken
as well and a mass balance was constructed for pellitorine,
which ranged between 103.6 and 132.4% total recovery. To
confirm the validity of the test, atenolol (50 𝜇M) and propra-
nolol (20𝜇M) were used as the negative (low permeability)
and positive (high permeability) control, respectively [19].
Pellitorine was quantified using a ultraperformance liquid
chromatography-tandem mass spectrometry (UPLC-MS2)
method as described below.
The apparent permeability coefficient (𝑃app in cm/s) of
pellitorine inDS2was calculated using a sink condition equa-
tion, while 𝑃app of pellitorine in DS1 was calculated using a
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nonsink equation. From Fick’s first law, 𝐽 = −𝐷×[𝑑𝐶(𝑥)]/𝑑𝑥
(𝐽 is the flux or transfer rate along the donor-to-receptor side,
𝐷 is the diffusion coefficient, 𝑥 is the distance from the donor
compartment, and 𝐶(𝑥) is the concentration in the barrier
at the coordinate 𝑥 in the barrier), the following differential
equation is derived: 𝑑𝑀
𝑟
(𝑡)/𝑑𝑡 = 𝑃app×𝐴×[𝐶𝑑(𝑡)−𝐶𝑟(𝑡)], in
which 𝑃app is the apparent permeability coefficient (a product
of distribution coefficient with diffusion coefficient divided
by the barrier thickness), 𝑀
𝑟
is the amount of substance in
the receiver chamber, 𝐴 is the cross-sectional area of the
barrier, 𝐶
𝑑
is the donor concentration, and 𝐶
𝑟
is the receiver
concentration. This differential equation can be solved to
calculate 𝑃app using different initial conditions depending
on sink or nonsink conditions. In case of sink conditions,
the following equation was obtained from the amount of
compound transported per time 𝑑𝑀
𝑟
(𝑡)/𝑑𝑡 with the receiver
concentration set to zero [18, 20]:
𝑀
𝑟
(𝑡)
𝐶
𝑑,0
= 𝑃app × 𝐴 × 𝑡 + 𝑐, (1)
where 𝑃app is the apparent permeability coefficient (cm/s), 𝐴
is the surface area of the filter (1.12 cm2), 𝐶
𝑑,0
is the initial
concentration in the donor chamber (𝜇g/mL), 𝑡 is the time (s),
and 𝑐 is a constant term which vanishes, since𝑀
𝑟
is initially
zero at 𝑡 = 0.
The donor concentration at each time point was calcu-
lated by taking into account the amount of compound which
already permeated through the cell monolayer during that
time interval. In this way, the reduction in donor concentra-
tion after every sampling was also taken into account. The
cumulative fraction transported FAcum (cm) is defined as
FAcum =
1
𝐴
×
𝑖
∑
𝑘=1
[𝐶
𝑟
(𝑡
𝑘
) − 𝑓 × 𝐶
𝑟
(𝑡
𝑘−1
)] × 𝑉
𝑟
[𝐶
𝑑
(𝑡
𝑘−1
) + 𝐶
𝑑
(𝑡
𝑘
)] /2
= 𝑃app × 𝑡𝑖
(2)
in which 𝑉
𝑟
is the volume of the receiver compartment (mL),
𝑓 is the sample replacement dilution factor (1 − 𝑉
𝑠
/𝑉
𝑟
with
𝑉
𝑠
being the sample volume), 𝑡
𝑖
(s) is the time at sampling
𝑖, 𝑡
𝑘
(s) is the time at sampling 𝑘, 𝐶
𝑟
(𝑡
𝑘
) (𝜇g/mL) is the
experimentally determined concentration of pellitorine in
the receiver compartment at sampling 𝑘, and 𝐶
𝑑
(𝑡
𝑘
) (𝜇g/mL)
is the experimentally determined concentration of pellitorine
in the donor compartment at sampling 𝑘. 𝐶
𝑑
is considered as
constant and is obtained by taking the average of 𝐶
𝑑
of the
start and the end of the time interval.𝑃app was calculated from
the slope of the cumulative fraction versus time curve using
a linear fit.
In case of nonsink conditions, the differential equation
resulted in the following solution [18, 20]:
𝐶
𝑟
(𝑡) = [
𝑀
𝑉
𝑑
+ 𝑉
𝑟
] + (𝐶
𝑟,𝑡−1
× 𝑓 − [
𝑀
𝑉
𝑑
+ 𝑉
𝑟
])
× 𝑒
−𝑃app×𝐴×(1/𝑉𝑑+1/𝑉𝑟)×Δ𝑡
(3)
in which 𝑀 (𝜇g) is the total amount of pellitorine in the
system at time 𝑡, 𝑉
𝑑
(mL) is the volume of the donor com-
partment,𝐶
𝑟,𝑡−1
(𝜇g/mL) is the concentration of pellitorine in
the receiver compartment at the previous time point, 𝑡 is the
time (s), Δ𝑡 (s) is the time at time 𝑡 minus the previous time
point, and 𝐶
𝑟
(𝑡) (𝜇g/mL) is the concentration of pellitorine
in the receiver compartment at time 𝑡. Minimisation of the
sum of squared residuals (SSR) was used on the nonlinear
curve fitting to obtain the𝑃app.The uptake and efflux ratio are
calculated as 𝑃app,𝑎𝑏/𝑃app,𝑏𝑎 and 𝑃app,𝑏𝑎/𝑃app,𝑎𝑏, respectively.
2.4. In Vivo Pharmacokinetic Experiment with Rats
2.4.1. Animals. Male and female Wistar rats weighing
approximately 220 g were obtained from Bharat Serum
and Vaccines Pvt. Ltd., Thane, India (registration number
103/99/CPCSEA) and were housed at CU Shah College of
Pharmacy, SNDT Women’s University, Santacruz, Mumbai,
India (registration number 39/99/CPCSEA) where the exper-
iments were carried out. Rats of 7-8 weeks of age were fasted
overnight and used for the experiments.
2.4.2. Pharmacokinetic Experiment. A pellitorine dose solu-
tion was prepared using the Anacyclus pyrethrum extract.
To the rats, 1.5mL of a 0.73mg pellitorine/g dose solution
in 10 : 20 : 30 : 40 (w/w/w/w) EtOH : PG :Vit E-TPGS : PEG
400 was administered using a gavage needle (stainless steel,
length of 3 inches, and 2.5mm internal diameter). As blank, a
solution containing EtOH, PG,Vit E-TPGS, and PEGwithout
pellitorine was used. Each dose solution was orally adminis-
tered to three female and three male rats. 1.5mL blood was
collected from the retro orbital vein at 1, 2, 3, 4, 6, and 8 h after
administration of the dose solution and was centrifuged for
20min at room temperature. Thereafter, the serum samples
were immediately frozen at −80∘C until bioanalysis. The
animals were sacrificed at the end of the experiment by CO
2
inhalation. Using GraphPad software (La Jolla, USA), the
elimination rate constant 𝑘
𝑒
(h−1) is calculated using the
following equation of a one-compartment model: 𝐶(𝑡) =
𝐶
0
× 𝑒
−𝑘𝑒×𝑡, in which 𝐶(𝑡) (ng/mL) is the concentration of
pellitorine at time 𝑡 (h) and𝐶
0
the concentration of pellitorine
at time 𝑡 = 0 (ng/mL). The elimination half-life 𝑡
1/2,𝑒
(h) is
calculated as ln(2)/𝑘
𝑒
.
2.5. In Vivo Blood-Brain Barrier Experiment with Mice
2.5.1. Animals. Seven-to-ten-week-old female, Institute for
Cancer Research, Caesarean Derived-1 (ICR-CD-1) mice
(Harlan Laboratories, Venray, Netherlands) weighing 29–
32 g were used for the BBB transport experiments. The
experiments were performed according to the Ethical Com-
mittee principles of laboratory animal welfare as approved by
Ghent University (Faculty of Veterinary Medicine, number
EC2014/128).
2.5.2. Blood-to-Brain Transport. An in vivo multiple time
regression (MTR) analysis was performed in order to deter-
mine whether pellitorine could enter the brain. A dose
solution of 1.8mg/mL pure pellitorine dissolved in 6.9%
EtOH, 2.5% dimethylacetamide, and 0.5% tween 80 (all
w/w) diluted in lactated Ringer’s solution containing 1% BSA
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was prepared. After anesthetizing the mice intraperitoneally
with a 40% (w/V) urethane solution (3 g/kg), the jugular
internalis vein and carotid artery were isolated and 20𝜇L
of the pellitorine dose solution was injected into the jugular
vein. After 1, 3, 5, 10, 12.5, and 15min after injection (with start
and end in duplicate), blood was collected from the carotid
artery. Immediately thereafter, the mice were decapitated and
the brains were isolated. Serum was obtained by centrifuging
the collected blood at 10 000×g for 15min at 21∘C.As negative
and positive control, I125- BSA and dermorphin were used,
respectively, to ensure the validity of the experiment [21–23].
The serum concentrations of pellitorine were plotted against
the time (expressed inmin).The curve was fitted using a first-
order kinetic, two-compartment model: 𝐶(𝑡) = 𝐶
1
× 𝑒
−𝛼×𝑡
+
𝐶
2
× 𝑒
−𝛽×𝑡, in which 𝐶 is the concentration of pellitorine in
serum at time 𝑡, 𝛼 and 𝛽 are hybrid constants, dependent
on the rate constants 𝑘
𝑒
(elimination rate constant), 𝑘
1,2
(rate constant between central and peripheral tissue com-
partment), 𝑘
2,1
(rate constant between peripheral tissue and
central compartment), 𝐶
1
is the concentration obtained after
extrapolation of the distribution phase 𝛼 to the 𝑦-axis, and
𝐶
2
is the concentration obtained after extrapolation of the
elimination phase 𝛽 to the 𝑦-axis. The ratio of the pellitorine
brain and serum concentration (𝜇L/g) was plotted versus the
exposure time (𝜃), which is a derived time variable of the
Gjedde-Patlak plot, to determine the BBB influx kinetics of
pellitorine [24, 25].
The exposure time is computed as 𝜃 = ∫𝑇
0
((𝐶
𝑠
(𝑡) ⋅
𝑑𝑡)/𝐶
𝑠
(𝑇)) and is defined as the integral of the concentration
of pellitorine in serum from start (𝑡 = 0min) to time 𝑇,
divided by the concentration of pellitorine in serum at time
𝑇. The integral of the concentration of pellitorine in serum
from zero to time 𝑇 is the area under the curve until time 𝑇.
The brain uptake of pellitorine was fitted using a biphasic
model, as elaborated by Wong et al. [26]:
𝐶brain (𝑇)
𝐶
𝑠
(𝑇)
= 𝐾 ⋅ 𝜃 + 𝑉
𝑔
⋅ (1 − 𝑒
(−𝜃⋅((𝐾1−𝐾)/𝑉𝑔))) + 𝑉
0
𝐾=0
≅ 𝑉
𝑔
⋅ (1 − 𝑒
(−𝜃⋅(𝐾1/𝑉𝑔))) + 𝑉
0
(4)
in which 𝐶brain(𝑇) is the concentration of pellitorine in
the brain at time 𝑇 (ng/g), 𝐶
𝑠
(𝑇) the concentration of
pellitorine in serum at time 𝑇 (ng/𝜇L), 𝐾 the net clearance
(𝜇L/(g⋅min)), 𝑉
𝑔
the tissue brain distribution volume (𝜇L/g),
𝐾
1
the unidirectional clearance from pellitorine from blood
to brain (i.e., the unidirectional brain transfer coefficient, also
referred to as influx rate) (𝜇L/(g⋅min)), and 𝑉
0
the vascular
brain distribution volume (𝜇L/g). The vascular distribution
volume of the negative control BSA (14.8 𝜇L/g) was used as
𝑉
0
to calculate the brain kinetic parameters of pellitorine.
2.5.3. Capillary Depletion. A capillary depletion experiment
was performed to distinguish the transport of pellitorine into
the brain, represented by the parenchyma, and part of pelli-
torine which is trapped by the endothelial cells of the brain,
represented by the capillaries. Amethod of Triguero et al. [27]
was used, which was modified by Gutierrez et al. [28, 29].
Themice were anesthetized intraperitoneally with 40% (w/V)
urethane solution (3 g/kg).Thereafter, 20 𝜇L of the 1.8mg/mL
pellitorine dose solution was injected into the jugular vein.
Tenmin after injection, blood was collected from the abdom-
inal aorta and serum was obtained by centrifuging the blood
at 10 000×g during 15min at 21∘C. Then, after removing the
skin of the mice’s chest, the aorta is clamped, the jugular
veins are severed, and the brain is immediately perfused
manually with 20mL of Lactated Ringer’s solution. The mice
are decapitated, and the brains are isolated, weighed, and
put into tubes (LoBind Eppendorf), to which 525𝜇L ice-
cold capillary buffer (10mM HEPES, 141mM NaCl, 4mM
KCl, 2.8mM CaCl
2
, 1 mM MgSO
4
, 1 mM NaH
2
PO
4
, and
10mM D-glucose adjusted to pH 7.4) was added. The tubes
(LoBind Eppendorf) were homogenized. Next, 1000𝜇L of
26% ice-cold dextran solution in capillary buffer was added
and vortexed and the tubes were subsequently centrifuged
at 20 000×g for 60min at 4∘C. Parenchyma and fat tissue
(supernatant) were transferred into separate tubes (LoBind
Eppendorf) and weighed.The capillaries (pellet) were kept in
the original tube.The sample preparation of the pellet and the
supernatant is the same sample preparation method as used
for themice brains andmice serum, respectively, as described
in Section 2.6.
The distribution in the brains was calculated as follows:
Fraction (%) =
𝑀tissue
𝑀capillaries +𝑀parenchyma
× 100 (5)
in which𝑀tissue is the amount of pellitorine in the capillaries
and parenchyma, 𝑀capillaries the amount of pellitorine in
the capillaries, and 𝑀parenchyma the amount of pellitorine
in the parenchyma. The capillary depletion experiment was
performed in duplicate and mean values are reported.
2.5.4. Brain-to-Blood Transport. To evaluate the efflux of pel-
litorine out of the brain into the blood, a previously described
in vivo method was used [29]. Briefly, the ICR-CD-1 mice
were anesthetizedwith 40% (w/V) urethane solution (3 g/kg).
Then, the skin of the skull was removed and a hole was
made into the lateral ventricle using a 22G needle marked
with tape at 2mm at the following coordinates: 1mm lateral
and 0.34mm posterior to the bregma. Using a syringe pump
(KDS100, KR analytical, Cheshire, UK), 1𝜇L of the 1.8mg/mL
pellitorine dose solution as used for the blood-to-brain influx
experiment was injected intracerebroventriculary (ICV) at a
speed of 360 𝜇L/h for 10 s.Themicewere decapitated after 1, 3,
5, 10, 12.5, and 15min after injection. Just before decapitation,
blood was collected from the abdominal aorta and serum
was obtained by centrifuging the blood at 10 000×g during
15min at 21∘C. Thereafter, brains were collected. The natural
logarithm of the pellitorine concentration in brain (ng/g)
was plotted versus time. The efflux rate constant 𝑘out (min
−1)
is obtained from the negative value of the slope of the
linear regression, applying first-order kinetics. From 𝑘out, the
efflux brain half-life (𝑡
1/2,brain) (min) is calculated as follows:
𝑡
1/2,brain = ln(2)/𝑘out.
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2.5.5. In Vitro Metabolic Stability of Pellitorine. The in vitro
metabolic stability of pellitorine was evaluated in mouse
brain and liver homogenates and mouse serum according
to previously described protocols [22, 30]. Using the Pierce
Modified Lowry Protein Assay method (Thermo Scientific),
the protein content of each tissue homogenate was deter-
mined to prepare a stock solution containing a 0.6mg/mL
protein concentration in Krebs-Henseleit buffer (pH 7.4).
Briefly, 75 𝜇Lof a 0.25mg/mLpellitorine solution dissolved in
2% (V/V) EtOH in Krebs-Henseleit buffer pH 7.4 containing
3% (m/V) BSA was incubated in 375𝜇L of serum/organ
homogenate and 300 𝜇L of Krebs-Henseleit buffer pH 7.4
while shaking at 750 rpm at 37∘C. After 0, 5, 7.5, 15, 60,
and 120min, aliquots of 100 𝜇L were taken and transferred
into 0.5mL tubes (LoBind Eppendorf) containing 100 𝜇L
of 1% (V/V) TFA in water. Next, the samples were heated
at 95∘C for 5min and subsequently cooled for 30min in
ice. Thereafter, the samples were centrifuged (20 000×g for
30min at 5∘C) and 25 𝜇L of the clear supernatant was injected
and analysed using aHPLC-UV/MSmethod of 46minwhich
was previously described [15]. The HPLC-MS analysis was
done on a HPLC system which consisted of a Spectra System
SN4000 interface, a Spectra System SCM1000 degasser, a
Spectra System P1000XR pump, a Spectra System AS3000
autosampler, and a Finnigan LCQ Classic ion trap mass
spectrometer in positive ion mode (all from Thermo, San
Jose´, CA, USA) equipped withWaters 2487 Dual Absorbance
detector and Xcalibur 2.0 software (Thermo) for data acqui-
sition. Control solutions were also prepared but without
pellitorine. Furthermore, control reference solutions were
prepared as well with a prior heat inactivation or without
tissue homogenate.
2.6. Bioanalytics
2.6.1. Serum Sample Preparation. To 60 𝜇L of 4% (V/V)
aqueous H
3
PO
4
solution and 30 𝜇L of the IS solution, 60 𝜇L
of the serum samples was added to a 0.5mL tube (LoBind
Eppendorf) and vortexed. Bymeans of solid phase extraction
using a positive pressure-96 processor (Waters, Zellik, Bel-
gium), interfering compounds were removed. The sorbent in
each well of the HLB Oasis 𝜇elution 96-well plate (Waters,
Zellik, Belgium) was preconditioned with 200 𝜇L of MeOH
and equilibrated using 200𝜇L of ultrapure water. Thereafter,
100 𝜇L of the previous serum sample solution was loaded,
followed by two washing steps using 200 𝜇L of 5% MeOH in
H
2
O and 200𝜇L of 20% MeOH in H
2
O, respectively. Two
times 25𝜇L ACN was used to elute pellitorine. 25 𝜇L of a
80 : 20 (V/V) H
2
O :MeOH solution was added to the eluate
and analysed with a UPLC-MS2method, as described further
in Section 2.6.3.
The bioanalytical method for the quantification of pel-
litorine in serum was basically validated using rat serum,
based upon the European Medicines Agency (EMA) guide-
line on bioanalytical method validation (EMEA/CHMP/
EWP/192217/2009) [31]. The limit of detection (LoD) (𝑆/𝑁 =
3) and limit of quantification (LoQ) (𝑆/𝑁 = 10) of pellitorine,
determined on the reference standard, were calculated as
0.19 ng/mL and 0.62 ng/mL, respectively, which correspond
to 0.36 ng/mL and 1.16 ng/mL in serum, respectively. Amatrix
factor of 0.97 was observed for pellitorine in serum. The
quantification of pellitorine in the mouse serum samples
was performed using a calibration curve with pellitorine
standards in 40 : 33.33 : 26.67 (V/V/V) MeOH :ACN :H
2
O.
The quantification of pellitorine in the rat serum samples
was performed using a preextracted spikedmatrix calibration
curve. Linearity was ensured in a working range from
0.62 ng/mL up to 101 ng/mL, corresponding to 1.16 ng/mL to
189 ng/mL in serum (𝑅2 = 0.9997).
The accuracy of the references used for the calibration
curves with pellitorine standards in 40 : 33.33 : 26.67 (V/V/V)
MeOH :ACN :H
2
O, the preextracted spiked matrix samples,
and the quality control (QC) conformed to the specifications,
namely, <15% of the nominal value and for the lower limit of
quantification (LLoQ) < 20% of the nominal value. Precision
was expressed as the coefficient of variation (CV).Thewithin-
run CV value did not exceed 15% for the preextracted spiked
matrix samples. Also the CV for the LLoQ sample did not
exceed 20% and thus all conform to the specification limits.
The recovery in serum was 90.65% (18.8 ng/mL to 189 ng/mL
in serum concentration range), calculated from the slopes of
the preextracted and postextracted spiked matrix samples.
No significant carry-over was observed (<20% of LLoQ
pellitorine and <5% for IS). The selectivity conformed to the
specifications (placebo serum < 20% of LLoQ pellitorine and
<5% for IS).
2.6.2. Brain Sample Preparation. The weighed mice brains
were transferred into test tubes, 1.0mL of the IS solution
in ACN was added, and the brains were crushed. The
brains were shaken for 4 h at 110 rpm at room temperature
using an Eppendorf centrifuge 5810 (Eppendorf, Rotselaar,
Belgium). Thereafter, the test tube was centrifuged at 250×g
for 5min and 800𝜇L of the supernatant was transferred into
other tubes (LoBind Eppendorf). Then, these test tubes were
centrifuged again at 20 000×g for 5min at room temperature
and 750 𝜇L of the supernatant was evaporated to dryness
under nitrogen. Pellitorine was redissolved in 175 𝜇L 90 : 10
(V/V) H
2
O :ACN and 160 𝜇L of this solution was loaded on
the HLB Oasis 𝜇elution 96-well plate. The same washing and
elution steps were applied as for the serum samples.
Again, a basic validation of the bioanalytical method for
the quantification of pellitorine in brains was performed.
The LoD and LoQ of pellitorine were 41.2 pg/g and 135 pg/g
in brain, respectively. A matrix factor of 0.98 was observed
for pellitorine in mice brains. Quantification of pellitorine
in the brain samples was performed using the preextracted
spiked matrix calibration curve (𝑅2 = 0.9982). Linearity was
demonstrated in a working range of 0.69 ng/mL to 100 ng/mL
pellitorine, corresponding to 135 pg/g to 19.6 ng/g in brain.
The accuracy of the references used for the calibration curves
and the QC samples with the preextracted spiked matrix
samples conformed to the specification limits (<15% of the
nominal value, LLoQ < 20% of the nominal value), except for
one QC reference preextracted spiked matrix sample (17% of
the nominal value instead of <15%), but was still acceptable
for our purposes. The within-run CV value did not exceed
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15% for the preextracted spiked samples. Also the LLoQ
did not exceed 20% and thus all conform to the limits. The
recovery in mouse brains was 115.5% (0.98 to 19.6 ng/g brain
concentration range).
2.6.3. UPLC-MS2 Method. A UPLC-MS2 method using an
Acquity UPLC RP C18 column (50 × 2.1mm, 1.7 𝜇m,
Waters, Zellik, Belgium) with a suitable guard column was
used for the quantification of pellitorine, developed on an
Acquity UPLC chromatograph coupled to a Xevo TQ-S
mass spectrometer (MS) (Waters, Zellik, Belgium) equipped
with a triple quadrupole mass analyser and an electrospray
ionisation (ESI) source. The column temperature was kept
at 30∘C, while the sample compartment remained constant
at 5∘C. The injection volume was 2 𝜇L and the flow rate was
set to 0.5mL/min. A mobile phase was applied consisting
of solvent A (0.1% FA in 30 : 70 (V/V) H
2
O :MeOH) and
solvent B (0.1% FA inMeOH) in gradient mode as follows: 0–
1.6min 100 : 0 (V/V) A : B, 1.6–2min going from 100 : 0 (V/V)
A : B to 0 : 100 (V/V) A : B, 2-3min 0 : 100 (V/V) A : B, 3–
3.4min going from 0 : 100 (V/V) A : B to 100 : 0 (V/V) A : B,
and 3.4–5min 100 : 0 (V/V) A : B. A needle wash solvent of
60 : 40 (V/V) DMSO :ACN was used. The MS operated in
ESI+mode with an optimised cone voltage of 50V, a capillary
voltage of 3.0 kV, and a source offset of 60V. Cone and des-
olvation gas (N
2
) flows were 180 and 1000 L/h, respectively,
while desolvation and source temperatures were set at 500∘C
and 150∘C, respectively. Acquisition was performed in the
multiple reaction monitoring (MRM) mode with m/z 224.11
to m/z 80.84 transition. The collision gas was argon and the
applied collision energy was 26 eV. By means of MassLynx
software (V4.1 SCN 843, Waters, Zellik, Belgium), data were
acquired and analysed.
3. Results
3.1. Caco-2 Cell Permeability. Our results demonstrated that
pellitorine was able to permeate the Caco-2 cell monolayer in
both directions: from the apical-to-basolateral side and from
the basolateral-to-apical side. The percentages of pellitorine
from the applied dose solutions (DS1 andDS2) which perme-
ated through the Caco-2 cells in the course of time are shown
in Figure 1. After 120min, 56.7% (or 0.31 𝜇g pellitorine) of the
applied pellitorinewithDS1 and 9.98% (or 2.24𝜇g pellitorine)
of the applied pellitorine with DS2 permeated the Caco-2
cell monolayer in the apical-to-basolateral direction. In the
basolateral to apical direction, the percentage of pellitorine
which permeated through the Caco-2 cells after 120min
is 23.7% (or 0.39 𝜇g pellitorine) with DS1 and 1.84% (or
1.24 𝜇g pellitorine) with DS2. 𝑃app,𝑎𝑏 of the positive control
propranolol resulted in 19.1 ⋅ 10−6 cm/s and similar values are
documented in literature [32]. The negative control atenolol
showed a lower permeability compared to propranolol.
Apparent permeability coefficients of pellitorine of
48.08 ± 0.08 ⋅ 10
−6 cm/s (mean ± SD, 𝑛 = 2) and
5.50 ± 0.06 ⋅ 10
−6 cm/s (mean ± SD, 𝑛 = 2) in case
of DS1 and DS2, respectively, were calculated for the
apical-to-basolateral transport. For the opposite direction
(basolateral-to-apical), 𝑃app values of pellitorine obtained
with DS1 and DS2 are 57.49 ± 6.20 ⋅ 10−6 cm/s (mean ± SD,
𝑛 = 2) and 2.80 ± 0.09 ⋅ 10−6 cm/s (mean ± SD, 𝑛 = 2),
respectively. Uptake ratios of 0.84 and 1.96 using DS1 and
DS2, respectively, are obtained.
3.2. Oral Gavage Experiment. The pellitorine serum concen-
trations after oral gavage are plotted against time (Figure 2).
Pellitorine was able to permeate the intestinal barrier in vivo.
The curve was fitted according to a one-compartment
model. An elimination rate constant and half-life of 0.28 h−1
and 2.46 h were obtained.
3.3. Blood-Brain Barrier Transport Kinetics of Pellitorine.
Using the MTR method, pellitorine showed a significant
influx into the mouse brain. In Figure 3, the ratio of the
concentration of pellitorine in brain and serum is plotted
versus the exposure time. The data were fitted using a bipha-
sic model, based on the modified Gjedde-Patlak equation
according to Wong et al. [26]. Pellitorine showed a very high
and rapid influx into the brains and a 𝐾
1
of 153 𝜇L/(g⋅min)
was determined. Moreover, the tissue brain distribution
volume (𝑉
𝑔
) is 792𝜇L/g. After about 10min exposure time,
a plateau was observed, which is consistent with the efflux of
pellitorine out of the brain.
Dermorphin (positive control) clearly showed an
influx with a calculated unidirectional influx rate of
0.26 𝜇L/(g⋅min). The negative control BSA gave a very small,
almost negligible brain influx, with a 𝐾
1
of 0.12 𝜇L/(g⋅min).
Both controls thus indicated a good performance of the
test and are in compliance with those previously reported
[29, 33].
The MTR data allowed us to evaluate the elimination
kinetics of pellitorine in serum as well. The serum profile
of pellitorine followed a two-compartment model. 𝐶
1
was
7.02 𝜇g/mL and 𝐶
2
was 0.44 𝜇g/mL. The distribution rate
constant𝛼was 1.56min−1, while the elimination rate constant
𝛽 was 0.15min−1 and an elimination half-life of 4.48min was
obtained.
3.4. Capillary Depletion. The fraction of pellitorine that was
taken up by the brain parenchyma and the fraction of
pellitorine which was trapped in the endothelial cells of
the brain capillaries were investigated. 97% of pellitorine
(corresponding to 347.3 𝜇L/g) transferred effectively into the
brain parenchyma, versus a low percentage of pellitorine
remaining in the brain capillaries: 3% (corresponding to
10.0 𝜇L/g). The high absolute values in the brain parenchyma
are consistent with the MTR results.
3.5. Brain-to-Blood Transport Kinetics of Pellitorine. A signif-
icant efflux of pellitorine out of the brain into the blood was
observed after intracerebroventricular injection of the dose
solution (Figure 4). The efflux behavior can explain the rapid
plateauing observed during the brain influx experiment. The
efflux transfer constant 𝑘out was calculated as 0.05min
−1,
equal to 𝑡
1/2,brain of 13.8min.
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Figure 1: The percentages of pellitorine from the applied dose solutions using dose solution 1 (DS1) and dose solution 2 (DS2) which
permeated through the Caco-2 cells monolayer in the course of time. Apical-to-basolateral transport and basolateral-to-apical transport
experiments of pellitorine were performed in duplicate (individual results in the same figure).
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Figure 2: Concentration of pellitorine in rat serum (ng/mL)
as a function of time (h) after oral gavage of pellitorine (5mg
pellitorine/kg body weight). Data are fitted according to a one-
compartment model (𝑛 = 2-3, mean, error bars: SEM).
3.6. In Vitro Metabolic Stability of Pellitorine. The stability
of pellitorine was determined in mouse serum, mouse brain
homogenate, and mouse liver homogenate. The results of
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Figure 3: Blood-to-brain transport (multiple time regression exper-
iment) results of pellitorine in mice.The ratio of pellitorine concen-
tration in brain versus serum (𝜇L serum/g brain) is plotted versus
the exposure time (min). Start and end point were performed in
duplicate. The data were fitted using a biphasic model.
this study indicate that pellitorine was stable for one hour in
serum, in brain as well as in liver (91%–105% recovery).
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Figure 4: Brain-to-blood transport results of pellitorine in mice.
The natural logarithm of the concentration of pellitorine in the brain
(ng/g) as a function of the time (min) is given.
4. Discussion
To characterize the intestinal absorption of pellitorine, the
permeability of pellitorine through Caco-2 cells was investi-
gated using two different dose solutions.The ethanol percent-
age in both dose solutionswas less than 0.5%.Thepermeation
level of pellitorine through Caco-2 cells was higher from
the absorptive apical-to-basolateral side (10–57%), compared
to the permeation from the basolateral-to-apical side (2–
24%). Pellitorine, applied as DS1, better permeated the Caco-
2 cells monolayer compared to pellitorine applied as DS2
in both directions, indicating that cosolvents (vitamin E-
TPGS, PEG 400, PG) did not influence the permeation level
through the cells in a positive way. However, the esterified
vitamin E derivative, vitamin E-TPGS, was added to increase
the solubility and facilitate the permeation of pellitorine
[34, 35]. The 𝑃app values obtained for pellitorine (0.3 ⋅ 10
−5
to 5.8 ⋅ 10−5 cm/s) were all above 1 ⋅ 10−6 cm/s, suggesting
an almost complete intestinal absorption, and are similar
to values reported by Matthias et al. [36] of the mono-
and diene-NAAs from Echinacea plant species. Given the
physicochemical properties of pellitorine (log𝑃 = 3.65,
MW = 223.36 g/mole), transcellular passive diffusion seems
favourable for pellitorine [37]. This was confirmed in our
study, as for both dose solutions containing pellitorine, the
ratio of 𝑃app values between the apical-to-basolateral and
the basolateral-to-apical direction or vice versa was ≤ 2,
indicating that no active transport was involved [38]. As the
efflux ratios were not greater than two, there is no efflux of
pellitorine. Next to this in vitro evaluation of the intestinal
barrier properties of pellitorine, a confirmatory in vivo oral
gavage experimentin rats was performed. A liquid dose
solution of pellitorine also containing EtOH, PG,Vit E-TPGS,
and PEG 400 was orally administered to rats. Pellitorine
diffused through the gut barrier and was observable in rat
serum. These results confirm the outcome of the initial in
vitro Caco-2 cell permeability study. The elimination half-
life of pellitorine was 2.46 h, which is in the same range
as the elimination half-life of 1.20 h, obtained by Woelkart
et al. [39], who investigated the plasma concentration of
dodeca-2E,4E,8E,10E/Z-tetraenoic acid isobutylamides from
Echinacea via oral gavage in rats.
Once in the blood, pellitorine can distribute to extravas-
cular compartments in order to exert a biological func-
tion. In the present study, the blood-brain barrier transport
characteristics of pellitorine were explored in an in vivo
mice experiment. Pellitorine was intravenously injected to
the mice in a solution containing EtOH and dimethylac-
etamide, which are both frequently used as cosolvents in
injectable pharmaceutical formulations, and tween 80, which
is a traditional surfactant, and diluted in lactated Ringer’s
solution containing BSA [40, 41]. In our study, no toxicity was
observedwhen performing the experiment and it is likely that
the solvents did not have an influence on the BBB integrity, as
lower doses are used than doses reported in literature which
can cause blood-brain barrier disruption. A dose of tween
80 up to 30mg/kg and 1–4 g/kg ethanol can disrupt the BBB,
while in this study only 3mg/kg tween 80 and 0.04 g EtOH/kg
body weight were administered [42]. In the current study,
a high initial unidirectional influx rate of 153𝜇L/(g⋅min)
was observed, indicating that pellitorine rapidly penetrated
the BBB after administration, which is consistent with the
lipophilicity of pellitorine. In addition, pellitorine was dis-
tributed in the brains as follows: 97% in the parenchyma
and only 3% in the capillaries, making it plausible to exert
CNS effects. Badhe et al. [43] already showed antidepressant
activity of a hydroalcoholic Anacyclus pyrethrum root extract
(50, 100, and 200mg/kg, p.o.) in albino mice. Another study
demonstrated the anticonvulsant and myorelaxation activity
of an ethanolic AP root extract in albinomice. A dose depen-
dent effect was observed against maximum electroshock test
and rotarod test after intraperitoneal administration of the
extract in doses of 200, 400, and 600mg/kg [44]. Sujith et al.
[14] evaluated neuropharmacological activity of an ethanolic
AP root extract (50, 100, and 200mg/kg, p.o.) in albino
Wistar rats. Nootropic activity was observed in rats in a
dose dependent way using the elevated plus maze (EPM)
test. Furthermore, the extract also showed antidepressant
activity in a forced swim test. Another study showed the
anticonvulsant activity against pentylenetetrazole (PTZ) of a
hydroalcoholic root extract of AP after oral administration
of 50, 100, 250, and 500mg/kg to Wistar rats. The observed
effect was dose dependent. In addition, protection against
MES induced seizures was observed in a dose dependent
way after administration of the extract in doses of 250, 500,
and 1000mg/kg. Furthermore, the extract prevented seizure
induced oxidative stress and showed protective effects against
cognitive impairment in rats in a dose dependent manner
[45]. Sujith et al. [46] showed a dose dependent cognitive
improvement of an ethanolic root extract of AP (50, 100, and
200mg/kg) after oral administration to albino Wistar rats
in an EPM test and passive avoidance paradigms. Moreover,
the extract enhanced short-term social memory in a social
recognition task. Zaidi et al. [47] showed anticonvulsant
activity against PTZ in a dose dependent manner in mice
after administration of a chloroform AP root extract in a
concentration of 100, 200, 400, and 800mg/kg. Also, against
bicuculline, the 800mg/kg AP extract showed anticonvulsant
activity. Furthermore, anxiolytic behavior was also observed
in an EPM model after administration of 800mg/kg AP
extract. Administration of 1600mg/kg AP extract showed
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impairedmotor coordination in a rotarod test. Another study
showed that pretreatment of albino mice with 100, 250, and
500mg/kg (p.o.) hydroalcoholic root AP extract increased
myoclonic jerk latency and delay in the development of
kindling. Protection against memory deficit was observed
after pretreatment of the AP extract in doses of 100, 250,
and 500mg/kg (p.o.) in PTZ kindled mice by decreasing
oxidative stress and ROCK II expression [48]. Other research
demonstrated the anticonvulsant activity of an ethanolic root
extract of Anacyclus pyrethrum (200, 400mg/kg, p.o.) in
a MES model in albino mice. 400mg/kg AP extract was
protective against PTZ model [13].
In the previously described effect studies, the AP extract
was administered to rats or mice in doses ranging between
50 and 1600mg extract/kg body weight. Assuming that the
concentration of pellitorine is 1.55% w/w (determined on the
ethanolic AP extract used in this study), the pellitorine dose
ranges between 0.8 and 24mg/kg. Since our study showed a
maximum serum concentration of 26 ng/mL pellitorine after
oral administration of 5mg pellitorine/kg to rats (Figure 2)
and assuming pellitorine follows a linear kinetic, the max-
imum serum concentration of pellitorine in the previously
described effect studies is between 4.0 and 129.0 ng/mL. Our
BBB data (Figure 3) showed a brain/serum concentration
ratio of 792𝜇L/g at equilibrium, so that the brain concentra-
tions of pellitorine in the previous effect studies correspond to
3.2 to 102.1 ng pellitorine/g brain. Looking at compounds used
for the treatment of CNS diseases (e.g., multiple sclerosis,
experimental autoimmune encephalomyelitis, and epilepsy),
administered at efficacious doses, drug concentrations in the
brain ranging between 15 and 620 ng/g brain were found
[49–51]. Hence, our BBB study corroborates well with the
previously described effect studies using the AP extract and
the brain concentrations of other CNS-active drugs.
5. Conclusion
In the current study, the intestinal barrier properties of
pellitorine were investigated in vitro and in vivo. It was shown
that pellitorine was able to cross the Caco-2 cell monolayer
and the rat gut after oral administration. Furthermore, it
was demonstrated that, after intravenously administration
of pellitorine to mice, pellitorine significantly and rapidly
penetrated the BBB reaching the brain parenchyma. The
biphasic course of the influx can partly be explained by an
observed significant efflux of pellitorine out of the brain.
These pharmacokinetic findings support the observed activ-
ities using the Anacyclus pyrethrum extract in the treatment
of CNS diseases.
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